Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Challenges to achieving clinical transplantation tolerance
Alan D. Salama, … , William E. Harmon, Mohamed H. Sayegh
Alan D. Salama, … , William E. Harmon, Mohamed H. Sayegh
Published October 1, 2001
Citation Information: J Clin Invest. 2001;108(7):943-948. https://doi.org/10.1172/JCI14142.
View: Text | PDF
Spotlight

Challenges to achieving clinical transplantation tolerance

  • Text
  • PDF
Abstract

Authors

Alan D. Salama, Giuseppe Remuzzi, William E. Harmon, Mohamed H. Sayegh

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
The fate of alloreactive T cells. Upon antigen engagement and in the pre...
The fate of alloreactive T cells. Upon antigen engagement and in the presence of adequate costimulatory signals, the alloreactive T cell becomes activated, proliferates, and is subject to a number of different fates. The first is differentiation to an effector cell, orchestrating the immune response directed toward the target antigen. Some of the T cells will differentiate into memory cells, able to provide rapid recall responses upon antigenic restimulation. Other cells will have their effector functions terminated either by anergy or by apoptotic death (which may be passive or may involve activation-induced cell death [AICD]), or as a consequence of regulation by other cells or soluble factors. CTL, cytotoxic T lymphocyte; DTH, delayed-type hypersensitivity.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts